Articles

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 8 (2015): August, 2015 https://doi.org/10.3324/haematol.2015.126821